Literature DB >> 21490582

Derivation of thymic lymphoma T-cell lines from Atm(-/-) and p53(-/-) mice.

Rasika Jinadasa1, Gabriel Balmus, Lee Gerwitz, Jamie Roden, Robert Weiss, Gerald Duhamel.   

Abstract

Established cell lines are a critical research tool that can reduce the use of laboratory animals in research. Certain strains of genetically modified mice, such as Atm(-/-) and p53(-/-) consistently develop thymic lymphoma early in life (1,2), and thus, can serve as a reliable source for derivation of murine T-cell lines. Here we present a detailed protocol for the development of established murine thymic lymphoma T-cell lines without the need to add interleukins as described in previous protocols (1,3). Tumors were harvested from mice aged three to six months, at the earliest indication of visible tumors based on the observation of hunched posture, labored breathing, poor grooming and wasting in a susceptible strain (1,4). We have successfully established several T-cell lines using this protocol and inbred strains ofAtm(-/-) [FVB/N-Atm(tm1Led)/J] (2) and p53(-/-) [129/S6-Trp53(tm1Tyj)/J] (5) mice. We further demonstrate that more than 90% of the established T-cell population expresses CD3, CD4 and CD8. Consistent with stably established cell lines, the T-cells generated by using the present protocol have been passaged for over a year.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21490582      PMCID: PMC3169248          DOI: 10.3791/2598

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  8 in total

1.  Development and characterization of T cell leukemia cell lines established from SCL/LMO1 double transgenic mice.

Authors:  D S Chervinsky; D H Lam; X F Zhao; M P Melman; P D Aplan
Journal:  Leukemia       Date:  2001-01       Impact factor: 11.528

2.  Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc.

Authors:  Vishva Mitra Sharma; Jennifer A Calvo; Kyle M Draheim; Leslie A Cunningham; Nicole Hermance; Levi Beverly; Veena Krishnamoorthy; Manoj Bhasin; Anthony J Capobianco; Michelle A Kelliher
Journal:  Mol Cell Biol       Date:  2006-09-05       Impact factor: 4.272

3.  Pleiotropic defects in ataxia-telangiectasia protein-deficient mice.

Authors:  A Elson; Y Wang; C J Daugherty; C C Morton; F Zhou; J Campos-Torres; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

4.  Control of Atm-/- thymic lymphoma cell proliferation in vitro and in vivo by dexamethasone.

Authors:  Xianghong Kuang; Mingshan Yan; Na Liu; Virginia L Scofield; Wenan Qiang; Jodi Cahill; Williams S Lynn; Paul K Y Wong
Journal:  Cancer Chemother Pharmacol       Date:  2004-11-27       Impact factor: 3.333

5.  Tumor spectrum analysis in p53-mutant mice.

Authors:  T Jacks; L Remington; B O Williams; E M Schmitt; S Halachmi; R T Bronson; R A Weinberg
Journal:  Curr Biol       Date:  1994-01-01       Impact factor: 10.834

6.  Atm-deficient mice: a paradigm of ataxia telangiectasia.

Authors:  C Barlow; S Hirotsune; R Paylor; M Liyanage; M Eckhaus; F Collins; Y Shiloh; J N Crawley; T Ried; D Tagle; A Wynshaw-Boris
Journal:  Cell       Date:  1996-07-12       Impact factor: 41.582

7.  Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice.

Authors:  Susan E Browne; L Jackson Roberts; Phyllis A Dennery; Susan R Doctrow; M Flint Beal; Carrolee Barlow; Rodney L Levine
Journal:  Free Radic Biol Med       Date:  2004-04-01       Impact factor: 7.376

8.  Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers.

Authors:  Richard S Maser; Bhudipa Choudhury; Peter J Campbell; Bin Feng; Kwok-Kin Wong; Alexei Protopopov; Jennifer O'Neil; Alejandro Gutierrez; Elena Ivanova; Ilana Perna; Eric Lin; Vidya Mani; Shan Jiang; Kate McNamara; Sara Zaghlul; Sarah Edkins; Claire Stevens; Cameron Brennan; Eric S Martin; Ruprecht Wiedemeyer; Omar Kabbarah; Cristina Nogueira; Gavin Histen; Jon Aster; Marc Mansour; Veronique Duke; Letizia Foroni; Adele K Fielding; Anthony H Goldstone; Jacob M Rowe; Yaoqi A Wang; A Thomas Look; Michael R Stratton; Lynda Chin; P Andrew Futreal; Ronald A DePinho
Journal:  Nature       Date:  2007-05-21       Impact factor: 49.962

  8 in total
  7 in total

Review 1.  Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.

Authors:  Christopher G England; Lixin Rui; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-14       Impact factor: 9.236

2.  T-cell Dysfunction upon Expression of MYC with Altered Phosphorylation at Threonine 58 and Serine 62.

Authors:  Colin J Daniel; Carl Pelz; Xiaoyan Wang; Michael W Munks; Aaron Ko; Dhaarini Murugan; Sarah A Byers; Eleonora Juarez; Karyn L Taylor; Guang Fan; Lisa M Coussens; Jason M Link; Rosalie C Sears
Journal:  Mol Cancer Res       Date:  2022-07-06       Impact factor: 6.333

3.  Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma.

Authors:  Qiumin Tan; Lorenzo Brunetti; Maxime W C Rousseaux; Hsiang-Chih Lu; Ying-Wooi Wan; Jean-Pierre Revelli; Zhandong Liu; Margaret A Goodell; Huda Y Zoghbi
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-30       Impact factor: 11.205

4.  ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling.

Authors:  Steven Goossens; Enrico Radaelli; Odile Blanchet; Kaat Durinck; Joni Van der Meulen; Sofie Peirs; Tom Taghon; Cedric S Tremblay; Magdaline Costa; Morvarid Farhang Ghahremani; Jelle De Medts; Sonia Bartunkova; Katharina Haigh; Claire Schwab; Natalie Farla; Tim Pieters; Filip Matthijssens; Nadine Van Roy; J Adam Best; Kim Deswarte; Pieter Bogaert; Catherine Carmichael; Adam Rickard; Santi Suryani; Lauryn S Bracken; Raed Alserihi; Kirsten Canté-Barrett; Lieven Haenebalcke; Emmanuelle Clappier; Pieter Rondou; Karolina Slowicka; Danny Huylebroeck; Ananda W Goldrath; Viktor Janzen; Matthew P McCormack; Richard B Lock; David J Curtis; Christine Harrison; Geert Berx; Frank Speleman; Jules P P Meijerink; Jean Soulier; Pieter Van Vlierberghe; Jody J Haigh
Journal:  Nat Commun       Date:  2015-01-07       Impact factor: 17.694

5.  Single-cell sequencing reveals karyotype heterogeneity in murine and human malignancies.

Authors:  Bjorn Bakker; Aaron Taudt; Mirjam E Belderbos; David Porubsky; Diana C J Spierings; Tristan V de Jong; Nancy Halsema; Hinke G Kazemier; Karina Hoekstra-Wakker; Allan Bradley; Eveline S J M de Bont; Anke van den Berg; Victor Guryev; Peter M Lansdorp; Maria Colomé-Tatché; Floris Foijer
Journal:  Genome Biol       Date:  2016-05-31       Impact factor: 13.583

6.  Inhibition of USP14 Deubiquitinating Activity as a Potential Therapy for Tumors with p53 Deficiency.

Authors:  Yu-Shui Ma; Xiao-Feng Wang; Yun-Jie Zhang; Pei Luo; Hui-Deng Long; Liu Li; Hui-Qiong Yang; Ru-Ting Xie; Cheng-You Jia; Gai-Xia Lu; Zheng-Yan Chang; Jia-Jia Zhang; Shao-Bo Xue; Zhong-Wei Lv; Fei Yu; Qing Xia; Da Fu
Journal:  Mol Ther Oncolytics       Date:  2020-01-11       Impact factor: 7.200

7.  Transient genomic instability drives tumorigenesis through accelerated clonal evolution.

Authors:  Ofer Shoshani; Bjorn Bakker; Lauren de Haan; Andréa E Tijhuis; Yin Wang; Dong Hyun Kim; Marcus Maldonado; Matthew A Demarest; Jon Artates; Ouyang Zhengyu; Adam Mark; René Wardenaar; Roman Sasik; Diana C J Spierings; Benjamin Vitre; Kathleen Fisch; Floris Foijer; Don W Cleveland
Journal:  Genes Dev       Date:  2021-07-15       Impact factor: 11.361

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.